Reirradiation of primary brain tumours: survival, clinical response and prognostic factors

Citation
T. Veninga et al., Reirradiation of primary brain tumours: survival, clinical response and prognostic factors, RADIOTH ONC, 59(2), 2001, pp. 127-137
Citations number
45
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Onconogenesis & Cancer Research
Journal title
RADIOTHERAPY AND ONCOLOGY
ISSN journal
01678140 → ACNP
Volume
59
Issue
2
Year of publication
2001
Pages
127 - 137
Database
ISI
SICI code
0167-8140(200105)59:2<127:ROPBTS>2.0.ZU;2-1
Abstract
Background.and purpose: First, the aim was to determine the survival and qu ality of life after reirradiation of relapsing primary malignant brain tumo urs. The second aim was to assess the influence of a set of potentially pro gnostic factors on survival. Materials and methods: Forty-two patients received reirradiation for recurr ing primary brain tumours. The interval between the two consecutive treatme nts was at least 1 year. External beam irradiation for the initial and recu rrent tumour was usually delivered with two opposing lateral fields or two wedged fields in orthogonal directions. The median physical doses of the fi rst and second radiation course were 50 and 46 Gy, respectively. The median cumulative biological equivalent doses (BED) were 200.4 (alpha/beta = 2 Gy ) and 115.2 Gy (alpha/beta = 10 Gy). During follow-up, corticosteroid medic ation and the WHO-performance were registered at regular intervals. The rad iological response was assessed by reviewing all available CT- and MRI-film s. Potentially prognostic factors with respect to survival were evaluated b y both univariate and multivariate analyses. Results: A clinical response (i.e. clinical improvement) was seen in 24% of the patients. Of the evaluable patients, nearly one-third showed a complet e (8%) or partial (22%) radiological response. The median overall survival (OS) and progression-free survival (PFS) after retreatment were 10.9 and 8. 6 months, respectively. By multivariate analysis, four independent prognost ic factors for survival were identified: (1), the WHO-score before retreatm ent (P = 0.002); (2), the length of the interval between treatments (P = 0. 008); (3), the tumour histology; and (4), the response to initial treatment (P values, 0.04). The median survival times for patients with WHO-scores o f 0-1 and greater than or equal to2 were 14.0 and 7.4 months, respectively. Patients with oligodendrogliomas had a median OS of 27.5 months, whereas p atients with astrocytomas had a median OS of 6.9 months after retreatment. Long-term complications of retreatment were seen in three patients, all of whom had a cumulative BED2 of >204 Gy (with alpha/beta = 2 Gy). The quality of life after retreatment, however, was well preserved in the majority of patients. They remained ambulant and capable of self-care until the time of progression which occurred after 8.6 months (median PFS). Conclusions: After an initial treatment with radiation up to tolerance leve ls of normal brain tissue, reirradiation of recurring primary brain tumours seems feasible. During the time until clinical progression, patients remai ned independent with a reasonable quality of life. (C) 2001 Elsevier Scienc e Ireland Ltd. All rights reserved.